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INTRODUCTION
Calcium channel blockers have been used for
more than 30 years to treat a variety of cardiovascu-
lar diseases including angina, arrhythmias and hy-
pertension (1). Nifedipine [1,4-dihydro-2,6-dimethyl-
4-(2-nitropheyl)-3,5-pyridinedicarboxylic acid di-
methyl ester] is a 1,4-dihydropyridine-derivative
calcium channel blocker widely used for treatment
of hypertension and angina. Over the past decade,
many clinical studies have suggested that nifedipine
has not only hypotensive effects but also cardiovas-
cular organ and kidney-protective effects in patients
with cardiovascular and kidney diseases (1-4, 5). In
addition, it has been reported that nifedipine ame-
liorates endothelial dysfunctions (6-10) through an
anti-apoptotic effect (11, 12) in human endothelial
cells. However, it is unlikely that nifedipine exerts
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these effects through its calcium channel-blocking
property because endothelial cells do not have
voltage-dependent L-type calcium channels, which
are thought to be the target of 1,4-dihydropyridine
derivatives (13). In addition, nifedipine exerts a
direct effect on endothelial cell permeability by in-
hibiting protein kinase C and attenuates Nuclear
Factor-KappaB (NF-κB) activation, which are in-
dependent of its calcium channel-blocking activity
(14, 15). These observation suggest that nifedipine
has organ protective effects including renoprotec-
tion, at least in part, beyond its antihypertensive
actions. However its detailed mechanisms have
not been identified as yet. Some researchers claimed
that the antioxidant activity may be one possible
mechanism responsible for the organ-protective ef-
fects of 1,4-dihydropyridine calcium channel block-
ers (16-18). However, the antioxidant activity of
nifedipine is reported to be less prominent than
that of other 1,4-dihydropyridine calcium channel
blockers (16, 17).
Nifedipine is extremely sensitive to light and can
be converted to its nitroso analog, nitrosonifedipine
[2,6-dimethyl-4-(2-nitrosopheyl)-3,5-pyridinedicar-
boxylic acid dimethyl ester] (NO-NIF), under nor-
mal room illumination (19-25) (Fig. 1). On the other
hand, NO-NIF is also enzymatically produced from
nifedipine without exposure to light (26). The ability
of NO-NIF to block calcium channels is quite weak
or non-existent compared with that of nifedipine
(27-29). Meanwhile, it was reported that NO-NIF
showed a prominent free-radical scavenging activity
for 2,2’ -azo-bis(2-amidinopropane)-derived al-
kylperoxyl radicals than that of Trolox-C, a water-
soluble vitamin E analogue (30). In the previous
report, we had demonstrated that NO-NIF changed
to a NO-NIF radical when it interacted with un-
saturated fatty acids, a major component of lipid
bilayer, and the NO-NIF radicals responsible for
the radical scavenging activity and following pre-
vention of lipid peroxidation (31). Glomerular en-
dothelium is a fundamental layer in the glomerulus
in order to protect the glomerulus from atherogenic
insults (32). Therefore, dysfunction of glomerular
endotherial cells is responsible for the renal diseases
progression such as chronic kidney disease (CKD)
(33, 34). These observations have led us to hypothe-
size that NO-NIF would be a critical molecule in the
renal glomerular protective effects of nifedipine.
Meanwhile, up-regulation of tumor necrosis factor-
alpha (TNF-α) is accomplished by inflammation
reactions (35), and associated with the development
or exacerbation of kidney diseases such as nephrotic
syndrome (36), septic acute renal failure (37), renal
ischemia-reperfusion injury (38), cisplatin-induced
nephrotoxicity (39), and type 1 diabetes (40). There-
fore, in this study, we investigated the ability of
NO-NIF to protect endothelial cells from cumene
hydroperoxide (Cum-OOH)-induced inflammation
(35) and TNF-α induced cell toxicity using cultured
human glomerular endothelial cells (HGECs).
MATERIALS AND METHODS
Materials
Nifedipine, methanol, and cumene hydroperox-
ide (Cum-OOH) were purchased from Wako Pure
Chemical Industries (Tokyo, Japan). 6-Hydroxy-
2,5,7,8 - tetramethyl - chroman -2 - carboxylic acid
(Trolox -C) was obtained from Tokyo Kasei Co.
(Tokyo, Japan). TNF-α (human, recombinant) was
from Roche Diagnostics (Germany). Anti intra-
cellular adhesion molecule-1(anti ICAM-1) anti-
body was from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). NO-NIF was prepared from
nifedipine according to a previous report (31). All
other reagents were of analytical grade. Water was
demineralized and further purified using a Milli-Q
system from Millipore (Bedford, MA, USA).
Cell culture
HGECs and CS-C complete medium (including
10% serum) or serum-free CS-C medium were pur-
chased from the Cell Systems (Kirkland, WA, USA).
HGECs were cultured at a density of 1105 cells/
ml in 60 mm dishes or 24-well plates (Iwaki Glass
Co., Ltd.) in CS-C complete medium at 37in an
incubator containing 5% CO2 and used within five
passages.
Figure 1. Chemical structure of nifedipine (A) and NO-NIF (B).
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Cell viability assay
The cell damage induced by Cum-OOH and TNF-
α and its attenuation by NO-NIF was evaluated by
assessing the reduction of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium (MTT) as previously
described (41). Briefly, 90% confluent HGECs in
24-well culture plates were washed twice with phos-
phate buffered saline (PBS) then incubated with
or without test reagent in CS-C complete medium
for 6-h. Following 24-h incubation with TNF-α or
with Cum-OOH, culture medium was sucked out
then added 500 μL of MTT-containing serum free
CS-C medium and after a further 3-h incubation.
HGECs were lysed with 10% SDS solution contain-
ing 0.01N HCl, and the amount of formozan was
assessed by measuring the absorption at 590-nm
using a spectrophotometer as an index of the cell
viability. The cell viability (%) was calculated using
the following formula :
Cell viability (%) = 100A590 (sample)/A590
(negative control)
Western blotting analysis of ICAM-1
HGECs were grown to 90% confluency on 60
mm dish with CS-C complete medium then treated
with TNF-α at indicated time and concentration in
each figure legend. Thereafter, the incubation me-
dia were discarded, washed twice with ice-cold
Ca2+- and Mg2+-containing PBS and lysed in 500 μL
of lysis buffer (20 mM Tris-HCl, pH7.4, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM β -glycero-
phosphate, 1 mM sodium orthovanadate, 1 μg/ml
leupeptin, and 1 mM phenylmethylsulfonyl fluo-
ride). After subjecting the cells to a freeze-thaw
cycle, the cell lysates were transferred to micro-
centrifuge tubes, sonicated (Handy Sonic UR-20
P ; Tomy Seiko Co., Ltd.) on ice, and then centri-
fuged at 20,000 xg for 20 min at 4. The protein
amounts in the cell extracts were determined us-
ing a protein assay kit (BIO-RAD, Hercules, CA),
and the extracts were then stored at -80 until
use.
Western blotting analysis of ICAM-1 protein
expression in HGECs was carried out using an
ICAM-1-specific antibody. Briefly, the cell extracts
(20 μg of total protein per lane) were analyzed by
SDS-PAGE on a 10% polyacrylamide gel, and pro-
teins were transferred onto a PVDF membrane and
the blots were first blocked with 5% bovine serum
albumin for 3-h. Subsequently, the membrane was
incubated with a polyclonal rabbit anti-ICAM-1
antibody (1 : 2000 dilution) at room temperature
for 1-h, and the immunocomplex of ICAM-1 pro-
tein was then visualized followed by incubation with
ECL western-blotting kit and Hyperfilm ECL (GE
healthcare, Piscataway, NJ, USA) in accordance
with the manufacturer’s instructions. The signal
intensities of corresponding bands were determined
by a computerized densitometric analysis using
Image-J software.
Statistical analysis
Values are expressed as meansS.D. for 3-6
separate experiments. Data were analyzed using a
one-way analysis of variance was used to determine
significance among groups, after which a modified
t -test with the Bonferroni correction for compari-
son between groups. Values of p0.05 were ac-
cepted as statistically significant.
RESULTS
Effect of NO-NIF on Cum-OOH-induced cytotox-
icity
Since Cum-OOH is a lipid soluble hydroperox-
ide and known to induce lipid peroxidation and
apoptotic cell damage (42) through free radical re-
action (43), we investigated the HGECs viability fol-
lowing exposure to Cum-OOH. 24-h incubation of
Cum-OOH significantly and dose dependently de-
creased cell viability in HGECs (Fig. 2). To investi-
gate the antioxidant activity of NO-NIF to the Cum-
OOH, HGECs were pretreated with 10 μM NO-NIF
Figure 2. Effect of Cum-OOH on viability of HGECs.
HGECs were exposed to various concentrations of Cum-OOH
for 24 h. Thereafter the cell viability was examined using a MTT
assay as described in Materials and Methods. Results were ex-
pressed as a percentage of control. Values are the meanSD
(*p0.05 compared with control, n = 6).
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for 6-h and following 24-h incubation in the pres-
ence of 100 μM Cum-OOH. As shown in Fig. 3, the
cell viability was significantly recovered by the ad-
dition of NO-NIF (909% of control), which was to
the same extent as Trolox-C (805% of control)
but not by nifedipine (6414% of control).
Effect of NO-NIF on TNF-α-induced cytotoxicity
Firstly, to assess the cytotoxic effect of TNF-α
on HGECs, the cells were exposed to various con-
centrations of TNF-α for 24h, and the cell viability
was then determined by analyzing the reduction of
MTT to formazone as an index of the viable cells.
As shown in Fig. 4, TNF-α reduced the number of
viable cells in a dose-dependent manner, and the
approximately 90.66.4%, 78.02.3% and 62.711%
reduction of the cell viability was observed at the
concentrations of 1, 3 and 10 ng/ml, respectively.
Then, to examine the cytoprotective effect of NO-
NIF, the HGECs were pretreated with10 μM NO-
NIF for 6-h following 24-h treatment with 10 ng/
ml TNF-α, and the cell viability was determined
by measuring MTT reduction under the same ex-
perimental conditions. As shown in Fig. 5, the re-
duction of cell viability induced by TNF-α・ was
completely blocked by pretreatment of the cells
with NO-NIF, but not with nifedipine. In addition,
Trolox C, a water-soluble derivative of vitamin E
with antioxidant activity, also completely protected
the cells against the cytotoxic effect of TNF-α to
the same extent as NO-NIF.
TNF-α induced ICAM-1 protein expression in
HGECs
To examine the effect of TNF-α・ on ICAM-1 pro-
tein expression in HGECs, the cells were treated
with various concentrations of TNF-α for different
time periods, and the amounts of ICAM-1 protein in
the cells were determined by a immunoblotting tech-
nique. As shown in Fig. 6, TNF-α increased ICAM-
1 protein expression in HGECs in a manner de-
pending upon the time and concentration of TNF-
α treatment. The significant elevation of ICAM-
1 protein expression was observed by exposing
the cells to 10 ng/ml of TNF-α for at least 6 h, and
Figure 3. Protective effect of NO-nif on Cum-OOH-induced
damage to HGECs.
HGECs were preincubated with 10 μM of each reagent (NO-NIF,
nifedipine, and Trolox-C) for 6 h, and then exposed to 100 μM
Cum-OOH for 24 h. The cell viability were then assessed using a
MTT assay as described in Materials and Methods. Results
were expressed as a percentage of those obtained from the
group of Cum-OOH alone. Values are the meanSD (*p0.05
compared with Cum-OOH(+) control, n = 6).
Figure 4. Effect of TNF-α on viability of HGECs.
HGECs were exposed to various concentrations of TNF-α for
24 h. Thereafter the cell viability was examined using a MTT
assay as described in Materials and Methods. Results were ex-
pressed as a percentage of control. Values are the meanSD
(*p0.05 compared with control, n = 5).
Figure 5. Protective effect of NO-NIF on TNF-α - induced dam-
age to HGECs.
HGECs were preincubated with 10 μM of each reagent (NO-NIF,
nifedipine, and Trolox-C) for 6-h, and then exposed to 10 ng/mL
TNF-α for 24-h. The cell viability was then assessed using a
MTT assay as described in Materials and Methods. Results were
expressed as a percentage of those obtained from the group of
TNF-α alone. Values are the meanSD (*p0.05 compared
with TNF-α (+) control, n = 5).
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also induced by exposing to the considerably low
concentration of TNF-α (1 ng/ml) for 12-h.
Effect of NO-NIF on TNF-α-induced ICAM-1 pro-
tein expression in HGECs
The effect of NO-NIF on TNF-α - induced ICAM-
1 protein expression in HGECs was examined to elu-
cidate a possible relation between TNF-α - induced
ICAM-1 protein expression and its toxic effect
on the cells. As shown in Fig. 7, TNF-α - induced
ICAM-1 protein expression was considerably re-
duced by the pretreatment of the cells with NO-
NIF in a concentration dependent manner. In con-
trast, nifedipine had no effect on TNF-α - induced
ICAM-1 protein expression even at the highest con-
centration used here.
DISCUSSION
Nifedipine is a dihydropyridine (DHP)-based L-
type calcium channel antagonists (44), and it has
been used for the treatment of hypertension and
angina pectoris since the 1960s. In addition to its
hypotensive and anti-anginal effects, pleiotropic
effects of nifedipine were recently reported : anti-
apoptotic, anti-inflammatory, and antioxidant effects
on endothelial cells that control the development and
progression of atherosclerosis (2, 7-12, 15, 45-48).
Endothelium is a fundamental layer in the arte-
rial wall for the local regulation of flow to organ like
the kidney, and the injury of it can be a critical in-
sult for the generation and progression of CKD
(32, 34). Therefore, nifedipine has been predicted
to be a candidate for treatment of CKD, but finds
equivocal effects on the progression of CKD from
the results of clinical trials including ALLHAT (The
Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial) and INSIGHT (Interven-
tion as a Goal in Hypertension Treatment) except
in the case of adequate control of blood pressure is
acheved by nifedipine (44). Furthermore, it was
reported that the treatment of CKD by nifedipine
is likely to worsen rather than improve due to the
development of gromerular hypertension caused
Figure 6. Time- and concentration-dependent effect of TNF-α
on ICAM-1 protein expression in HGECs.
HGECs were exposed to 10 ng/ml TNF-α for different time
periods (A), or incubated with various concentrations of TNF-α
for 12 h (B). Cell extracts were prepared and subjected to an im-
munoblotting analysis as described in Materials and Methods,
and the expression of ICAM-1 protein was then assessed by de-
termining the intensities of corresponding bands. Results were
normalized to the control, and expressed as a fold- increase.
Values are the mean SD (*p0.05 compared with non-
stimulated HGECs, n = 4).
Figure 7. Effect of NO-NIF and nifedipine on TNF-α - induced
ICAM-1 expression in HGEC.
HGECs were pretreated with various concentrations of NO-NIF
or nifedipine for 6 h, and then exposed to 10 ng/ml of TNF-α
for 12 h. Cell extracts were prepared and subjected to an im-
munoblotting analysis as described in Materials and Methods,
and the expression of ICAM-1 protein was then assessed by de-
termining the intensities of corresponding bands. Results were
normalized to the control, and expressed as a fold- increase. Val-
ues are the meanSD (*p0.05 compared with TNF-α (10 ng/
ml), n = 5).
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by its L-type channel blocking activity (44).
By the way, nifedipine is light-sensitive, and is
converted completely to its nitroso analog, NO-NIF
(Fig. 1) without further photochemical degradation
under ordinary light (26). In addition, it has been
reported that NO-NIF lost the L-type Ca2+-channel
blocking activity (29). To date, it has been reported
that NO-NIF reduced the alkylperoxyl radicals on
its nitroso aromatic group, the kinetic rate con-
stant was ten and two times higher than that of
nifedipine and Trolox-C (30), respectively, NO-NIF
reacted with unsaturated fatty acids to form nitrox-
ide radicals via a pseudo-Diels-Alder mechanism
(21, 49), and the NO-NIF radical played an essen-
tial role for antioxidative activity of NO-NIF (31).
These observations led us to hypothesize that
the NO-NIF can be a candidate for glomerular en-
dothelial protecting agent for CKD patients if it
possesses anti-inflammatory activity. Therefore in
the present study, we investigated the ability of
the NO-NIF to protect cells from inflammation-
derived insult induced by Cum-OOH and TNF-α
using HGECs.
When HGECs were stimulated by 100 μM Cum-
OOH, cell viability was significantly decreased and
the Trolox-C treatment almost completely recov-
ered, indicating that oxidative modulation of cell
membrane participated in the toxicity of Cum-OOH
as descrived previously (35, 50). The addition of 10
μMNO-NIF improved the cell viability either equal-
ing or suppressing the that of Trolox-C whereas
nifedipine did not (Fig. 3), and these results were
in good agreement with the order of radical scav-
enging activity as reported (30). These data sug-
gested that NO-NIF improves the cytotoxicity based
on its quenching activity against lipid peroxides as
demonstrated in cell-free system (31).
It is apparent that the up-regulation of TNF-α is
closely related to the development or exacerbation
of kidney diseases (36-40). As shown in Fig. 4, TNF-
α treatment showed cytotoxicity as reported (51).
Because TNF-α increases cellular oxidation (52),
which is responsible for cell damage. Therefore,
it was expected that antioxidative activity of NO-
NIF (31) contributes to the suppression of TNF-α -
induced cell damages, and that the NO-NIF could
suppress the expression of cell adhesion molecules,
because TNF-α stimulates expression of cell adhe-
sion molecules such as ICAM-1 through its inflam-
mation reaction activities (53-57). Indeed, ICAM-1
expression was augmented by TNF-α treatment in
a time and concentration dependent manner in
HGECs (Fig. 6), and 10 μMNO-NIF treatment sig-
nificantly diminished the expression of ICAM-1 in-
duced by TNF-α (81% of TNF-α treatment), but
nifedipine showed no effects (10 μM, 1022% of
TNF-α treatment) (Fig. 7). Furthermore, we had
demonstrated that NO-NIF suppressed the produc-
tion of superoxide anion radical, a kind of reactive
oxygen species, induced by LY83583 (31). Taking
this evidence together with our present study, the
suppression of TNF-α - induced ICAM-1 expression
by NO-NIF is suggested to be involved in its ROS
scavenging ability in HGECs.
In conclusion, we found that NO-NIF shows pro-
tective effects against Cum-OOH- and TNF -α -
induced cytotoxicity in HGECs through its antioxi-
dative properties (31). Because NO-NIF is one of
the metabolites of nifedipine (26) and its intrinsic
toxicity was equal to that of nifedipine in HGECs
(Figs 3 and 5), we expect that NO-NIF can be a
candidate for an antioxidant drug to protect glomeru-
lar endothelial cells against TNF-α -related diseases.
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